Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.
|
30949905 |
2019 |
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hence, our findings implicate C12orf48, termed PARP-1 binding protein (PARPBP), or its interaction with PARP-1 to be a potential molecular target for development of selective therapy for pancreatic cancer.
|
20931645 |
2011 |
Pancreatic carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PARI upregulation in pancreatic cancer cells or avian DT40 cells conferred DNA repair deficiency and genomic instability.
|
23436799 |
2013 |
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARI, an element of the homologous recombination pathway of DNA repair<i>,</i>is involved in the regulation of cell cycle and carcinogenesis in pancreatic cancer.
|
29805304 |
2018 |
Malignant neoplasm of pancreas
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PARI upregulation in pancreatic cancer cells or avian DT40 cells conferred DNA repair deficiency and genomic instability.
|
23436799 |
2013 |
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.
|
30949905 |
2019 |
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hence, our findings implicate C12orf48, termed PARP-1 binding protein (PARPBP), or its interaction with PARP-1 to be a potential molecular target for development of selective therapy for pancreatic cancer.
|
20931645 |
2011 |
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARI, an element of the homologous recombination pathway of DNA repair<i>,</i>is involved in the regulation of cell cycle and carcinogenesis in pancreatic cancer.
|
29805304 |
2018 |
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Significantly, PARI silencing compromised cancer cell proliferation in vitro, leading to cell-cycle alterations associated with S-phase delay, perturbed DNA replication, and activation of the DNA damage response pathway in the absence of DNA damage stimuli.
|
23436799 |
2013 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Knock-down of their human homologs (C1ORF112 and C12ORF48) in HeLa cells slowed growth, indicating that these genes of unknown function, identified by GeneFriends, may be involved in cancer.
|
23039964 |
2012 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Knock-down of their human homologs (C1ORF112 and C12ORF48) in HeLa cells slowed growth, indicating that these genes of unknown function, identified by GeneFriends, may be involved in cancer.
|
23039964 |
2012 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Significantly, PARI silencing compromised cancer cell proliferation in vitro, leading to cell-cycle alterations associated with S-phase delay, perturbed DNA replication, and activation of the DNA damage response pathway in the absence of DNA damage stimuli.
|
23436799 |
2013 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
PARI, an element of the homologous recombination pathway of DNA repair<i>,</i>is involved in the regulation of cell cycle and carcinogenesis in pancreatic cancer.
|
29805304 |
2018 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
PARI overexpression promotes genomic instability and pancreatic tumorigenesis.
|
23436799 |
2013 |
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings offered a preclinical proof-of-concept for PARI as candidate therapeutic target to treat PDAC.
|
23436799 |
2013 |
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of C12orf48 sensitized PDAC cells to agents causing DNA damage and also enhanced DNA damage-induced G2/M arrest through reduction of PARP-1 enzymatic activities.
|
20931645 |
2011 |
Bladder neck obstruction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transgenic (Tg) male mice overexpressing aromatase (Cyp19a1) under the ubiquitin C promoter in the estrogen-susceptible C57Bl/6J genetic background (AROM+/6J) developed inguinal hernia by 2 months and severe BOO by 9 to 10 months, with 100% penetrance.
|
21356374 |
2011 |
Cryptorchidism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
AROM(+) males present a multitude of severe structural and functional alterations in the reproductive organs, such as cryptorchidism associated with Leydig cell hyperplasia, dysmorphic seminiferous tubules, and disrupted spermatogenesis.
|
11356692 |
2001 |
Fanconi Anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we show that PARI knockdown suppresses the genomic instability of Fanconi Anemia/BRCA pathway-deficient cells.
|
22153967 |
2012 |
Gynecomastia
|
0.010 |
Biomarker
|
disease |
BEFREE |
AROM+ mice present several dysfunctions, such as adrenal and pituitary hyperplasia, cryptorchidism, Leydig cell hypertrophy and hyperplasia, and gynecomastia.
|
14982857 |
2004 |
Hernia, Inguinal
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Transgenic (Tg) male mice overexpressing aromatase (Cyp19a1) under the ubiquitin C promoter in the estrogen-susceptible C57Bl/6J genetic background (AROM+/6J) developed inguinal hernia by 2 months and severe BOO by 9 to 10 months, with 100% penetrance.
|
21356374 |
2011 |
Male infertility
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here, we utilized a transgenic mouse strain that overexpresses human CYP19, which encodes aromatase (AROM+ mice), and mice with knockout of Esr1, encoding estrogen receptor α (ERαKO mice), to analyze interactions between viable Leydig cells (LCs) and testicular macrophages that may lead to male infertility.
|
24762434 |
2014 |
Leydig cell hyperplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
AROM(+) males present a multitude of severe structural and functional alterations in the reproductive organs, such as cryptorchidism associated with Leydig cell hyperplasia, dysmorphic seminiferous tubules, and disrupted spermatogenesis.
|
11356692 |
2001 |